Weekend Healthcare Pulse: Cutting more than calories? GLP-1s and cancer risk

研报英文原文证据摘录

Weekend Healthcare Pulse: Cutting more than calories? GLP-1s and cancer risk

confusingly) also named GLP 0.078), pancreatic (HR 0.096), colorectal (HR 0.141), non-Hodgkin

(EHMT1) has been identified as a driver of leukemic cell survival - lymphoma (HR 0.145), and kidney cancer (HR 0.156). Versus

its inhibition induces apoptosis in CLL and promotes differentiation metformin the benefit was narrower but still significant for lung

in AML - raising the hypothesis that GLP-1RAs may exert direct (HR 0.086), pancreatic (HR 0.124), and breast cancer (HR 0.462).

epigenetic anti-leukemic effects via PI3K/AKT/mTOR pathway Tirzepatide also demonstrated lower all-cause mortality in both

suppression and NF-kB-mediated cytokine attenuation. comparisons, with absolute risk reductions of 4.8% versus insulin

and 0.6% versus metformin. The authors attributed the findings

The study leveraged the TriNetX global federated network (147 to tirzepatide's dual GLP-1/GIP mechanism but noted important

million patients, 112 healthcare organisations) to identify adults caveats - short median follow-up of around six months, inability to

with at least one leukemia risk factor, propensity matching 313,099 verify medication adherence, potential residual confounding from

GLP-1RA users 1:1 to controls, achieving good balance with unmeasured lifestyle factors, and limited generalizability outside

all standardised mean differences below 0.001. Across the full the US - all of which support the need for prospective validation

matched cohort of 626,198 patients, GLP-1RA use was associated before cancer prevention implications can be drawn.

with a 51% reduction in AML (HR 0.49, 95% CI 0.34-0.70,

p<0.0001), with the signal robust across age and BMI subgroups

and confirmed in a 12-month sensitivity analysis.